Latest CSL (ASX:CSL) News

Gold, rare earths and energy shares led a busy week, while major company results brought large gains and steep sell-offs. Corporate deals, new project studies and rising dividends drew buyers, but some stocks fell despite stronger earnings.

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.

CSL Limited’s FY2026 results reveal modest revenue growth offset by a multibillion-dollar statutory loss driven by restructuring and impairments, alongside a maintained dividend and a strategic focus on sustainable growth.

Capital raisings, resource updates and Medicare news drove the week’s biggest share moves. The sharpest gains came from silver and tungsten juniors, while the heaviest fall came from a deeply discounted equity raising.

CSL Limited’s interim CEO Gordon Naylor reveals a downgraded FY26 outlook amid slower growth and announces substantial impairments tied to CSL Vifor assets. Leadership changes and transformation efforts aim to restore momentum.

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

CSL Limited has released its half-year results showing a slight revenue decline amid ongoing transformation efforts, while maintaining its full-year guidance and expanding its share buyback program.

CSL Limited has announced an ordinary dividend of USD 1.30 per share for the six months ending December 2025, payable in April 2026 with multi-currency options for shareholders.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.

CSL Limited announces the retirement of CEO Dr Paul McKenzie, with veteran executive Gordon Naylor appointed as interim CEO and Managing Director. The leadership change marks a new chapter for the biotech giant amid ongoing strategic transformation.